GH

Guardant Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

111.80
+5.40
+5.08%
After Hours: 111.50 -0.3 -0.27% 16:56 09/25 EDT
OPEN
106.24
PREV CLOSE
106.40
HIGH
112.88
LOW
105.33
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
112.88
52 WEEK LOW
55.90
MARKET CAP
11.12B
P/E (TTM)
-88.1634
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Genetron: 3 Reasons To Stay Bullish On China's Early-Stage Cancer Screening
China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research.As the early cancer-screening technology matures, the commercial strategy at the current stage is more critical. In China's blue-ocean market, Genetron has the first-mover advantage in market deployment.GTH recently engaged in a national key cohort study at a scale of 10 thousand patients for prospective cancer research.Compared to pan-cancer detection developer Burning Rock, Genetron focuses on specific types and moves faster on business expansion.
Seekingalpha · 4h ago
FDA's liquid biopsy approval is a milestone for Guardant Health AMEA: CEO
Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid biopsy approval that can help in cancer detection and treatment.
CNBC.com · 16h ago
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 2d ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 3d ago
Illumina Announces $8 Billion Acquisition Of Former Cancer-Testing Spinoff Grail
Investor's Business Daily · 4d ago
Insider Weekends: Tamara Gustavson Puts $8 Million Into Public Storage
Insider buying increased significantly last week.Notable Insider Buys: Public Storage, IGM Biosciences, Inc., Cassava Sciences, Inc., Intra-Cellular Therapies, Inc., Nikola Corporation.Notable Insider Sells: Scientific Games Corporation, Guardant Health, Inc., Antero Midstream Corporation, The Boston Beer Company, Inc., Zscaler, Inc.
Seekingalpha · 4d ago
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Hedge Funds Keep Piling Into Guardant Health, Inc. (GH)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 09/11 15:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GH. Analyze the recent business situations of Guardant Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GH stock price target is 110.13 with a high estimate of 130.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 431
Institutional Holdings: 87.69M
% Owned: 88.20%
Shares Outstanding: 99.42M
TypeInstitutionsShares
Increased
140
14.37M
New
101
2.53M
Decreased
64
12.31M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.00%
Pharmaceuticals & Medical Research
+1.53%
Key Executives
Chairman/President/Chief Operating Officer/Director
AmirAli Talasaz
Chief Executive Officer/Director
Helmy Eltoukhy
Chief Financial Officer
DEREK BERTOCCI
Chief Financial Officer
Derek Bertocci
Chief Information Officer
Kumud Kalia
Other
Michael Wiley
Lead Director/Independent Director
Ian Clark
Director
Vijaya Gadde
Independent Director
Bahija Jallal
Independent Director
Samir Kaul
Independent Director
Stanley Meresman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GH
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Guardant Health Inc stock information, including NASDAQ:GH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GH stock methods without spending real money on the virtual paper trading platform.